(Q34386184)

1 August 2017

1 reference

title

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications (English)

1 reference

1 August 2017

1 reference

Reff ME

1

1 reference

PubMed ID

11578914

1 August 2017

Heard C

series ordinal

2

1 reference

1 August 2017

1 October 2001

1 reference

Critical Reviews in Oncology Hematology

1 August 2017

1 reference

1 August 2017

40

1 reference

1 August 2017

1

1 reference

1 August 2017

25-35

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Possible use of similar framework region amino acid sequences between human and mouse immunoglobulins for humanizing mouse antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Human antibodies from transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Production of fully human antibodies by transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Human antibody effector function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Improving antibody affinity by mimicking somatic hypermutation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

By-passing immunization: building high affinity human antibodies by chain shuffling

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Targeting of tumours with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: immunolocalisation, pharmacokinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Biological properties of a CD4 immunoadhesin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Abciximab. An updated review of its use in ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Taking engineered anti-CEA antibodies to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

BR96 sFv-PE40 immunotoxin: nonclinical safety assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900132-9

7 January 2021

10.1016/S1040-8428(01)00132-9

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11578914